Etrolizumab Population Pharmacokinetics (Pop PK) and Covariate Analysis in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

被引：0
|
作者：
Wei, Xiaohui [1 ]
Luca, Diana [1 ]
Wang, Yehong [1 ]
O'Byrne, Sharon [1 ]
Erickson, Rich [1 ]
Davis, John [1 ]
Tang, Meina [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2014年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1673
引用
收藏
页码：S496 / S496
页数：1
相关论文
共 50 条
  • [1] Etrolizumab population pharmacokinetics (Pop PK) and covariate analysis in patients with moderately to severely active ulcerative colitis (UC)
    Wei, X. T.
    Luca, D.
    Wang, Y.
    O'Byrne, S.
    Erickson, R.
    Davis, J. D.
    Tang, M. T.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S46 - S47
  • [2] Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Moein, Anita
    Lu, Tong
    Jonsson, Siv
    Ribbing, Jakob
    Kassir, Nastya
    Zhang, Wenhui
    Sperinde, Gizette
    Zhang, Rong
    Tang, Meina
    Oh, Young S.
    Bruno, Rene
    Zhu, Rui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1244 - 1255
  • [3] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [4] Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Kassir, Nastya
    Zhu, Rui
    Moein, Anita
    Langenhorst, Jurgen
    Ribbing, Jakob
    Zhang, Rong
    Tang, Meina T.
    Oh, Young S.
    Zhang, Wenhui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1234 - 1243
  • [5] Population Pharmacokinetic Modeling Analysis of Golimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Liao, Sam
    Marano, Colleen
    Strauss, Rick
    Zhang, Hongyan
    Johanns, Jewel
    Davis, Hugh M.
    Reinisch, Walter
    Feagan, Brian G.
    Sandborn, William
    GASTROENTEROLOGY, 2016, 150 (04) : S408 - S408
  • [6] Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Liao, Sam
    Strauss, Richard
    Reinisch, Walter
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 157 - 174
  • [7] Assessment of disease-related therapeutic protein drug-drug interaction (TP-DDI) for etrolizumab in patients with moderately to severely active ulcerative colitis (UC)
    Wei, X. T.
    Kenny, J.
    Dickmann, L.
    Maciuca, R.
    Looney, C.
    Khojasteh-Bakht, C.
    Tang, M. T.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S346 - S347
  • [8] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [9] Guselkumab for moderately to severely active ulcerative colitis
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [10] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
12345